⚠️ Where Silicon Valley is Wrong About AI
An article in The San Francisco Standard criticizes the focus on achieving AGI, pointing to the ignoring of regulations, governance, and economic incentives. For example, in biopharmaceuticals, drug development remains expensive and slow, and the patent system hinders the search for new targets.
🌍 A technological breakthrough in models does not guarantee implementation in the real sector without reform of the regulatory environment and changes to economic models.
👤 Understanding why progress in medicine or construction is slower than AI enthusiasts predict.
Source 1: https://sfstandard.com/2026/07/29/myth-ai-intelligence-medicine-regulation/